Moderna will submit its Covid-19 vaccine for emergency use approval in the U.S. Monday after new trial data showed it to be 94% effective at preventing the disease, findings that are consistent with earlier data from the Phase 3 clinical trial, - Forbes reports.
New findings from the Phase 3 clinical trial, which involved over 30,000 participants, showed the vaccine to be 100% effective at preventing severe Covid-19 and 94% at preventing the disease more broadly.
The company says the findings are consistent across various demographics, including age, gender and ethnicity.
No serious safety concerns were identified, the company said, with side effects limited to injection site pain, headaches and fatigue.
Off the back of the results, and having collected the requisite two months of safety data, Moderna says it will apply for emergency use authorization from the U.S.’s Food and Drug Administration, as well as seek conditional marketing authorization from the European Medicines Agency.
The company says it has been informed that the FDA will meet to consider the vaccine on Dec. 17.
20 million. That’s the total number of doses that Moderna expects to have ready to ship to the U.S. by the end of 2020, enough for 10 million people to be vaccinated as the vaccine requires two doses. The company says it is on track to manufacture between 500 million to 1 billion doses globally in 2021.
Speaking about the results, CEO Stéphane Bancel emphasized the vaccine’s high success rate and, in particular, its ability to prevent severe disease. “We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death,” Bancel said.
Moderna’s announcement Monday is significant for a number of reasons. Foremost, it is another proven vaccine heading towards authorization that will help tackle the Covid-19 pandemic that has infected and killed millions of people around the world. In this manner, it is more promising than the vaccine candidate from Pfizer and BioNTech, which has also been submitted for regulatory approval after promising trial results, as it requires much less onerous storage requirements. For science it is also a significant milestone, using RNA technology that has not yet managed to make it to market (Pfizer and BioNTech’s vaccine is also built using RNA). Finally, it is a big milestone for Moderna, should the vaccine be approved, as the company has not yet brought a vaccine to market.
See all the news
“აჭარისწყალი ჯორჯიას” ახალი აღმასრულებელი დირექტორი ჰყავს
Fines for Violation of Traffic Rules in Azerbaijan Amounted to USD 55 MLN during Jan-Sep 2020
Key Highlights in Global and Regional Markets
EASTERN EUROPEAN DNS FORUM WAS HELD IN GEORGIA
რატომ ვერ ვმართეთ კორონავირუსი? - #Forbesკვირა პროლოგი გიორგი ისაკაძე
Q&A: Ek Law Office
LVMH and Tiffany Agree on Lower Price for $16 Billion Takeover
Woman in Charge
Hualing FIZ: Four New International Companies to Establish Free Zone Businesses in Georgia
U.S. Investment Firm Asks Republic of Georgia for License to Mineral Rights on Block 12
Focus on Georgia - ADB
Focus on Ganja Gap in Nagorno-Karabakh’s Regional Conflict
Scientific Community Calls for Action Against Lockdowns
Georgian Government seize foreign-owned asset, referred to International Arbitration
Studying Abroad Costs Georgian Students €10,000–15,000
Franco Frattini - Georgia, straying from the rule of law
Letter to the Newsweek Editor: 'Russia Determined to Wield Power in Georgia'
Caspiannews: Georgia’s Actions to Seize Foreign Company Disrupt Telecommunications Corridor Between Europe & Asia
Key Markets Indicators